Frontage Holdings - 股票

Frontage Holdings 负债 2024

Frontage Holdings 负债

229.37 百万 USD

股票代码

1521.HK

ISIN

KYG3679P1019

在2024年,Frontage Holdings的负债总额为229.37 百万 USD,与上一年217.51 百万 USD负债相比,差异为5.45%

Frontage Holdings Aktienanalyse

Frontage Holdings在做什么?

Frontage Holdings Corp is an international pharmaceutical and biotechnology company founded in 2001 in Pennsylvania, USA. With its wide range of services in preclinical and clinical research, Frontage offers its customers innovative and cost-effective solutions to accelerate and optimize the development of new therapeutics and drug candidates. The core business of Frontage focuses on providing services in the areas of pharmacology, pharmacokinetics, toxicology, preclinical development, clinical development, and bioanalytical laboratory services. The company operates research laboratories in the USA and China and has extensive experience in collaborating with customers from the pharmaceutical and biotechnology industry, as well as academic institutions. Frontage has become a major pharmaceutical and biotechnology company serving customers in the USA, Europe, and Asia. As such, Frontage has become a key partner for companies looking to advance their drug candidates through the clinical phases of development. Frontage offers targeted and tailored services to meet the requirements of each project and can support customers in the rapid and cost-effective implementation of their goals. The various divisions of Frontage include pharmaceutical services, chemical development, bioanalysis, and DMPK (Disposition, Metabolism, Pharmacokinetics). Frontage's pharmaceutical services offer a wide range of preclinical and clinical development resources, including cell-based assays, drug metabolism and pharmacokinetic studies, as well as clinical trial management and execution. Frontage's chemical development division provides a wide range of expert services, including the synthesis of organic molecules, process development, and scalable production. Frontage's bioanalytical services offer a range of solutions for the quantitative determination of drugs and other biomolecules in biological samples such as blood and urine. This includes the use of advanced technologies such as mass spectrometry for compound identification and quantification. DMPK is an important division of Frontage, focusing on the absorption, metabolism, distribution, and excretion of drugs in the body and their occurrence in biological fluids such as blood and urine. Frontage utilizes its expertise in DMPK to help its customers optimize drug concentrations in the bloodstream and achieve optimal efficacy. Frontage has continuously expanded its services to meet the growing demands of the industry. The company has also focused on providing innovative technologies that can enhance the efficiency and accuracy of research and development. Frontage works closely with its customers to develop customized solutions that meet their specific requirements. Frontage has a proud history as a trusted partner in the pharmaceutical and biotechnology industry, offering its customers high-quality and reliable services. Through its effective and innovative research and development, Frontage supports its customers in the development of drugs that can help improve the lives of people worldwide. Frontage Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

负债的详细信息

Frontage Holdings的负债评估

Frontage Holdings的负债包括公司对外界各方和投资者的财务承诺和债务。它们分为短期负债,即一年内到期的负债,和长期负债,即在较长时间段内到期的负债。对这些负债的详细评估对于评价Frontage Holdings的财务稳定性、运营效率和长期可持续性至关重要。

年度对比

通过对Frontage Holdings的负债进行年度对比,投资者可以识别公司财务定位的趋势、变化和异常。负债总额的减少通常表明财务状况的强化,而增加则可能表明投资、收购的增加或可能的财务压力。

对投资的影响

Frontage Holdings的总负债在决定公司的杠杆作用和风险状况方面起到重要作用。投资者和分析师会仔细研究这个方面,以判断公司满足其财务承诺的能力,这将影响投资吸引力和信用评级。

负债波动的解读

Frontage Holdings的负债结构变化反映了其财务管理和战略的变化。负债的减少反映了高效的财务管理或债务偿还,而增加则可能表明扩张、收购行动或运营成本的增加,这些都会对投资者产生不同的影响。

关于Frontage Holdings股票的常见问题

Frontage Holdings今年的负债有多高?

Frontage Holdings今年的负债额为229.37 百万 USD。

Frontage Holdings的负债与去年相比高了多少?

Frontage Holdings的负债与去年相比,增加了5.45% 上升。

Frontage Holdings的投资者面临高负债的后果是什么?

对于Frontage Holdings的投资者来说,高额债务可能构成风险,因为它会使公司的财务状况变弱,可能会影响其履行责任的能力。

Frontage Holdings的投资者面临低负债率会有什么后果?

低债务意味着Frontage Holdings具有强大的财务地位,并且能够履行其义务,而不会过度负担其财务。

Frontage Holdings的负债增加会对公司产生什么影响?

Frontage Holdings的负债增加可能导致公司的义务增加,并可能更难以履行其财务责任。

Frontage Holdings的负债减少会对公司产生什么影响?

Frontage Holdings的负债减少可能意味着公司的负担较轻,并且拥有更强大的财务地位,这将使其更容易履行其财务义务。

是什么因素影响了Frontage Holdings的负债?

一些可能影响Frontage Holdings负债的因素包括投资、收购、运营成本和营业收入的发展。

Frontage Holdings的负债总额为何对投资者如此重要?

Frontage Holdings的负债对投资者来说很重要,因为它们是公司财务稳定性的指标,且能向投资者提供关于公司如何履行其财务义务的信息。

Frontage Holdings可以采取哪些战略措施来改变负债?

为了改变负债状况,Frontage Holdings可以采取的措施包括节约成本、提高销售额、出售资产、获得投资或建立合作伙伴关系等。企业进行全面的财务状况审查以选择最佳的战略措施是非常重要的。

Frontage Holdings支付多少股息?

在过去的12个月中,Frontage Holdings支付了 的股息。这相当于大约的股息收益率。在未来的12个月内,Frontage Holdings预计将支付0 USD的股息。

Frontage Holdings的股息收益率有多高?

Frontage Holdings当前的股息收益率为。

Frontage Holdings什么时候支付股息?

Frontage Holdings按季度支付股息。这些股息将在月份分发。

Frontage Holdings的股息有多安全?

Frontage Holdings 在过去0年里每年都支付了股息。

Frontage Holdings的股息有多高?

预计未来12个月的股息将达到0 USD。这相当于0 %的股息收益率。

Frontage Holdings位于哪个行业?

Frontage Holdings 被分配到“健康”板块。

Wann musste ich die Aktien von Frontage Holdings kaufen, um die vorherige Dividende zu erhalten?

要获得Frontage Holdings在支付的0 USD的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Frontage Holdings最后一次支付股息是什么时候?

上一次股息发放日期为。

Frontage Holdings在2023年的股息是多少?

在2023年,Frontage Holdings 分配了0 USD作为股息。

Frontage Holdings 的股息是以哪种货币支付的?

Frontage Holdings的股息将以USD的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Frontage Holdings

我们对Frontage Holdings 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Frontage Holdings 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: